Copyright
©The Author(s) 2021.
World J Hepatol. Jul 27, 2021; 13(7): 731-746
Published online Jul 27, 2021. doi: 10.4254/wjh.v13.i7.731
Published online Jul 27, 2021. doi: 10.4254/wjh.v13.i7.731
Beta blocker | Initial dose | Goal | Treatment duration | Further guidance |
Propranolol | 20–40 mg twice daily | Maximum dosage of 160 mg/day; Or until the resting heart rate of 55–60 beats/min; Maximum dosage of 80 mg/day in patients with ascites | Indefinite | Adapt every 2-3 d until optimal dose is reached; Discontinue during spontaneous bacterial peritonitis, hyponatremia (Na < 125 mmol/L) or acute kidney injury; Systolic blood pressure should not decrease below 90 mmHg; EGD for further variceal screening is not needed |
Carvedilol | 6.25 mg once daily | Maximum dosage of 12.5 mg/day | Indefinite | Adapt dose after 3 d and increase to 6.25 mg twice daily; Discontinue during spontaneous bacterial peritonitis, hyponatremia (Na < 125mmol/L) or acute kidney injury; Systolic blood pressure should not decrease below 90 mmHg; EGD for further variceal screening is not needed; Potential switch from carvedilol to propranolol in case of new onset of ascites |
Nadolol | 20-40 mg once daily | Maximum dosage of 160 mg/day; Or until the resting heart rate of 55–60 beats/min; Maximum dosage of 80 mg/day in patients with ascites | Indefinite | Adapt every 2-3 d until optimal dose is reached; Discontinue during spontaneous bacterial peritonitis, hyponatremia (Na < 125mmol/L) or acute kidney injury; Systolic blood pressure should not decrease below 90 mmHg; EGD for further variceal screening is not needed |
- Citation: Pfisterer N, Unger LW, Reiberger T. Clinical algorithms for the prevention of variceal bleeding and rebleeding in patients with liver cirrhosis. World J Hepatol 2021; 13(7): 731-746
- URL: https://www.wjgnet.com/1948-5182/full/v13/i7/731.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i7.731